EnvSeq-1 Envs HIV-1 vaccine (Duke University/NIAID)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameEnvSeq-1 Envs HIV-1 vaccine (Duke University/NIAID)

Drug Alias Namesequential HIV-1 gp120 envelope vaccine (Duke University/National Institute of Allergy and Infectious Diseases)CH505TF + CH505w53 + CH505w78 + CH505w100 combination HIV envelope vaccine (Duke University/NIAID)

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSouth Africa

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDuke University

China Registration ClassN/A

Develop Information

Active CompaniesDuke University National Institute Of Allergy And Infectious Diseases (Niaid)

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A